NDAORALTABLET
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYLOREL (guanadrel sulfate) is an oral antihypertensive agent approved in 1982 that works as an adrenergic inhibitor to reduce blood pressure. It is indicated for the treatment of hypertension, typically in patients who require additional blood pressure control. The drug acts by depleting norepinephrine stores in peripheral sympathetic neurons.
LOE Approaching
With LOE approaching and competitive pressure at 30%, this product faces declining market relevance, suggesting minimal team expansion and focus on managed decline or portfolio optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYLOREL offers limited career advancement opportunity given its LOE status and zero linked job openings. Roles are primarily defensive and focused on contract management rather than brand building, expansion strategy, or innovation.
Product Manager (Legacy)Managed Care Specialist
Worked on HYLOREL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.